NCT05168735View on ClinicalTrials.gov

Ketamine + Mindfulness for Depression

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

September 1, 2023

Conditions
Depression, Unipolar
Interventions
DRUG

Intravenous Ketamine

Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

BEHAVIORAL

Brief Mindfulness Exercises

30min guided training in mindfulness meditation immediately prior to infusion

BEHAVIORAL

Academic Exercises

30min of mental math and other academic cognitive puzzles completed silently/mentally

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic, Pittsburgh

All Listed Sponsors
lead

Rebecca Price

OTHER